COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination

Abstract

Since the coronavirus disease (COVID-19) pandemic hit the globe in early 2020, we have steadily gained insight into its pathogenesis; thereby improving surveillance and preventive measures. In contrast to other respiratory viruses, neonates and young children infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have a milder clinical presentation, with only a small proportion needing hospitalization and intensive care support. With the emergence of novel variants and improved testing services, there has been a higher incidence of COVID-19 disease reported among children and neonates. Despite this, the proportion of young children with severe disease has not increased. Key mechanisms that protect young children from severe COVID-19 disease include the placental barrier, differential expression of angiotensin-converting enzyme 2 (ACE-2) receptors, immature immune response, and passive transfer of antibodies via placenta and human milk. Implementing mass vaccination programs has been a major milestone in reducing the global disease burden. However, considering the lower risk of severe COVID-19 illness in young children and the limited evidence about long-term vaccine safety, the risk–benefit balance in children under five years of age is more complex. In this review, we do not support or undermine vaccination of young children but outline current evidence and guidelines, and highlight controversies, knowledge gaps, and ethical issues related to COVID-19 vaccination in young children. Regulatory bodies should consider the individual and community benefits of vaccinating younger children in their local epidemiological setting while planning regional immunization policies.

How did we protect children against COVID-19 in Iran? Prevalence of COVID-19 and vaccination in the socio-economic context of COVID-19 epidemic

“…Moreover, WHO [ 40 ] reported that during the initial pandemic phase with the ancestral strain, from December 2019 to October 2021, children under five years of age represented 2% of reported global cases and 0.1% of reported global deaths. According to a recent review study, key mechanisms that protect young children from severe COVID-19 disease include the placental barrier, differential expression of angiotensin-converting enzyme 2 (ACE-2) receptors, immature immune response, and passive transfer of antibodies via placenta and human milk [ 41 ]. Older children and younger adolescents (5 to 14 years) account for 7% of reported global cases and 0.1% of reported global deaths.…”

Increasing Vaccine Uptake during Pregnancy by Using Prenatal Education Classes: An Effective Tool for Health Communication and Promotion

“…Among general and specific advantages of vaccination during pregnancy, the primary ones are the prevention of maternal morbidity and mortality and the reduction of risks of intrauterine infection and fetal disease [ 38 ]. The key mechanism that protects neonates from severe infective diseases is associated with the passive transfer of antibodies via the placenta and human milk [ 39 ].…”

Utility of the Xpert Xpress CoV-2/Flu/RSV Plus Kit: A Glance at RSV Infection in Adults and Coinfection Rate

“…[ 5 ] Since the outbreak of the SARS-CoV-2 in 2019, >600 million people have been infected, resulting in >6 million deaths worldwide. [ 6 ]…”